Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?

European Journal of Health Economics

Volumn 15, Issue 3, 2014, Pages 223-228

  Farfan Portet, María Isabel ^a   Gerkens, Sophie ^a   Lepage Nefkens, Isabelle ^a   Vinck, Irmgard ^a   Hulstaert, Frank ^a  

^a BELGIAN HEALTH CARE KNOWLEDGE CENTRE KCE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; HUMAN GROWTH HORMONE; MONOCLONAL ANTIBODY; RECOMBINANT ERYTHROPOIETIN;

COST CONTROL; DRUG COST; HUMAN; PRIORITY JOURNAL; REVIEW; ECONOMIC ASPECT; ECONOMICS; EUROPE; FEE;

BIOSIMILAR PHARMACEUTICALS; COST CONTROL; ECONOMIC COMPETITION; EUROPE; FEES, PHARMACEUTICAL; HUMANS;

EID: 84898023506     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-013-0538-4     Document Type: Review

References (49)

1. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. Off. J. Eur. Union 28 November 2001, L 311
2. Rovira, J., Espín, J., García, L., Olry de Labry, A.: The Impact of Biosimilars' Entry in the EU Market. Andalusian School of Public Health, Granada (2011)
3. Borget, I., Grivel, T.: Biosimilaires et facteurs medico-economiques. Bull. Cancer 97(5), 589-595 (2010)
4. Grabowski, H., Long, G., Mortimer, R.: Implementation of the biosimilar pathway: economic and policy issues. Seton Hall Law Rev. 41(2), 511-557 (2011)
5. Moran, N.: Fractured European market undermines biosimilar launches. Nat. Biotechnol. 26(1), 5-6 (2008)
6. Chauhan, D., Towse, A., Mestre Ferrandiz, J.: The Market for Biosimilars: Evolution and Policy Options. Office of Health Economics OHE Research, London (2009)
7. Grabowski, H.G., Ridley, D.B., Schulman, K.A.: Entry and competition in generic biologics. Manag. Decis. Econ. 28(4-5), 439-451 (2007)
8. Ruiz, S., Calvo, G.: Similar biological medicinal products: lessons learned and challenges ahead. J. Generic Med. 8(1), 4-13 (2011)
9. Minghetti, P., Rocco, P., Del Vecchio, L., Locatelli, F.: Biosimilars and regulatory authorities. Nephron 117(1), c1-c7 (2011)
10. European Medicines Agency (EMA): European public assessment reports. http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedicines%2Flanding%2Fepar- search.jsp&murl=menus%2Fmedicines%2Fmedicines.jsp&mid= WC0b01ac058001d124&searchTab=searchByAuthType&alreadyLoaded= true&isNewQuery=true&status=Authorised&status=Withdrawn&status= Suspended&status=Refused&keyword=Enter+keywords&searchType= name&taxonomyPath=&treeNumber=&searchGenericType= biosimilars&genericsKeywordSearch=Submit (2012). Accessed 1 Feb 2013
11. World Health Organisation: Guidelines on the Use of International Nonpropietary Names (INNs) for Pharmaceutical Substances. World Health Organisation, Geneva (1997)
12. Feldman, R., Lobo, F.: Competition in prescription drug markets: the roles of trademarks, advertising, and generic names. Eur. J. Health Econ. 14, 667-675 (2013)
13. Rader, R.A.: Nomenclature of new biosimilars will be highly controversial. BioProcess Int. 9, 26-33 (2011)
14. Lepage-Nefkens, I., Gerkens, S., Vinck, I., Piérart, J., Hulstaert, F., Farfán-Portet, M.-I.: Barriers and opportunities for the uptake of biosimilar medicines in Belgium. In: Health Services Research (HSR), vol. 199. Belgian Health Care Knowledge Centre (KCE), Brussels (2013)
15. Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance, Directive 2001/83/EC on the Community code relating to medicinal products for human use. Off. J. Eur. Union L 348/74
16. Chantelot, E.: Introduction - Naming of Biotechnology Medicines, p. 98. WHO, Geneva (2006)
17. European Generic Medicines Association (EGA): EGA position paper on naming of biopharmaceuticals: a contribution to WHO "Review of International Nonproprietary Names (INN) for Biological and Biotechnological Substances". EGA, Brussels (2006)
18. Frank, R.G., Salkever, D.S.: Generic entry and the pricing of pharmaceuticals. J. Econ. Market. Strategy 6(1), 15 (1997)
19. Hughes, D.A.: Biosimilars: evidential standards for health technology assessment. Clin. Pharmacol. Ther. 87(3), 257-261 (2010)
20. Liefner, M.: Biosimilars: price dynamics in Europe. In: Matisson, N., Mestre-Ferrandiz, J., Towse, A. (eds.) Biosimilars: How Much Entry and Price Competition Will Result?, pp. 51-65. Office of Health Economics (OHE), London (2009)
21. Sheppard, A.: Navigating the biosimilars market: the market landscape for biosimilars is in flux, with limited penetration now, but with the potential for growth for those who can navigate the market. BioPharm Int. 24(Suppl 9), s12-s13 (2011)
22. Cornes, P.: The economic pressures for biosimilar drug use in cancer medicine. Target. Oncol. 7(Suppl 1), S57-S67 (2012)
23. Project Group on Market Access and Uptake of Biosimilars: What you need to know about biosimilar medicinal products. A consensus information document. European Commission, Brussels (2013)
24. Haustein R., de Millas C., Höer, A., Häussler, H.: Saving money in the European healthcare systems with biosimilars. GaBi J. 1(3-4), 6 (2011)
25. Miletich, J., Eich, G., Grampp, G., Mounho, B.: Biosimilars 2.0: guiding principles for a global "patients first" standard. MAbs 3(3), 318-325 (2011)
26. Hurtado, P., Vieta, A., Espinos, B., Badia, X.: Market access barriers for biosimilars in Spain and Germany: Epoetin ALFA example. Value Health 14(7), A336 (2011)
27. Kani, C., Litsa, P., Alexopoulou, E., Hatzikou, M., Delibasi, S., Geitona, M.: Striving for affordable treatments within the Greek environment: Do epoetin biosimilars help? Value Health 14(7), A412-A413 (2011)
28. Lebboroni, M., Rosti, G., Cerchiari, A., Katz, P.: Health economics analysis of pegfilgrastim in the prophylaxis of febrile neutropenia (FN) in Italy. Eur. J. Hosp. Pharm. Sci. Pract. 19(2), 172 (2012)
29. Lindner, L., Gimenez, E., Rovira, J., Espin, J., Olry, A., Leticia, G.: Biosimilars in the European market. Value Health 14(7), A338 (2011)
30. Loiacono, C., Sgroi, C., Coppolino, S., Cannata, A., Ferrara, R., Arcoraci, V., Cananzi, P., Savica, V., Schuemie, M., Caputi, A.P., Trifiro, G.: How much are biosimilars used in southern Italy?: a retrospective analysis of epoetin utilization in the local health unit of Messina in the years 2010-2011. BioDrugs 26(2), 113-120 (2012)
31. Long, M., Trout, J., Akpinar, P.: Biosimilars: HGH to TNFs, how will payers respond? Value Health 12(7), A240 (2009)
32. Shepelev, J., Rauland, M., Krattiger, C.: Biosimilars are not generics from payer perspective. Value Health 14(7), A351 (2011)
33. Toscani, M., Vogenberg, R., Nash, D., Peskin, S.: Issues associated with biologic agents: healthcare stakeholder survey. Value Health 14(3), A14 (2011)
34. Viejo Viejo, I.: Does launch price actually matter? Value Health 14(7), A353 (2011)
35. Blackstone, E.A., Fuhr Jr, J.P.: Biosimilars and innovation: an analysis of the possibility of increased competition in biopharmaceuticals. Future Med. Chem. 2(11), 1641-1649 (2010)
36. Howell, P.R.: Patient access issues and opportunities. Contract Pharma. http://www.contractpharma.com/issues/2012-05/view-features/access-to- biosimilars/ (2012). Accessed 1 Feb 2013
37. Jommi, C.: Biosimilar drugs: Economic issues and Italian market perspectives. Pharmacoecon. Italian Res. Articles 12(1), 17-31 (2010)
38. Aapro, M.S.: What does a prescriber think of biosimilars? Oncologie 13(5), 234-238 (2011)
39. Doloresco, F., Fominaya, C., Schumock, G.T., Vermeulen, L.C., Matusiak, L., Hunkler, R.J., Shah, N.D., Hoffman, J.M.: Projecting future drug expenditures: 2011. Am. J. Health Syst. Pharm. 68(10), 921-932 (2011)
40. Grabowski, H.G., Kyle, M., Mortimer, R., Long, G., Kirson, N.: Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman Act. Health Aff. 30(11), 2157-2166 (2011)
41. Heinzl, S.: Epoetin biosimilar: cost-saving potential is still not exhausted. Pharmazeutische Zeitung 153(42), 23 (2008)
42. Hoffman, J.M., Li, E., Doloresco, F., Matusiak, L., Hunkler, R.J., Shah, N.D., Vermeulen, L.C., Schumock, G.T.: Projecting future drug expenditures-2012. Am. J. Health Syst. Pharm. 69(5), 405-421 (2012)
43. Howell, P., Burich, M.: Will biosimilars fulfill their promise of affordability? Pharm. Process. 27(9), 36-39 (2012)
44. Mellstedt, H.: Biosimilar products-cheaper version of biological drugs: new possibilities within several therapeutic fields. Läkartidningen 106(23), 1563-1566 (2009)
45. Aapro, M., Cornes, P., Sun, D., Abraham, I.: Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer. Ther. Adv. Med. Oncol. 4(3), 95-105 (2012)
46. Simoens, S.: Health economics of market access for biopharmaceuticals and biosimilars. J. Med. Econ. 12(3), 211-218 (2009)
47. Simoens, S.: Biosimilar medicines and cost-effectiveness. Clinicoecon. Outcomes Res. 3(1), 29-36 (2011)
48. Simoens, S., Verbeken, G., Huys, I.: Market access of biosimilars: not only a cost issue. Oncologie 13(5), 218-221 (2011)
49. Simoens, S., Verbeken, G., Huys, I.: Biosimilars and market access: a question of comparability and costs? Target. Oncol. 7(4), 227-231 (2012).